Investors in ARS Pharmaceuticals to Seek Lead Plaintiff Role

New York, New York, (Newsfile Corp. - September 6, 2026), Faruqi & Faruqi, LLP, a leading national securities law firm, is reminding investors who purchased ARS Pharmaceuticals Inc. securities between March 9, 2026, and June 24, 2026, of the October 5, 2026, deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the company.

According to the firm, the lawsuit alleges that ARS Pharmaceuticals and its executives violated federal securities laws by making false or misleading statements and failing to disclose material adverse facts regarding the expected timeline for expanded insurance coverage of neffy through CVS Caremark. The complaint states that on June 24, 2026, ARS announced that no new commercial formulary additions or coverage decisions had been issued for neffy in the July 1, 2026, cycle, and that CVS Caremark had reserved its decision on expanded insurance coverage until January 2027. This news caused the company’s stock price to fall by $2.52, or 23.9%, closing at $8.02 per share on June 25, 2026, on unusually heavy trading volume.

Faruqi & Faruqi, LLP, which has recovered hundreds of millions of dollars for investors since its founding in 1995, is encouraging investors who purchased or acquired securities in ARS Pharmaceuticals during the specified period to contact the firm directly. Potential plaintiffs can discuss their legal rights and options by calling partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).

The court-appointed lead plaintiff is typically the investor with the largest financial interest in the relief sought, who directs and oversees the litigation on behalf of the class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice or remain an absent class member.

Faruqi & Faruqi, LLP, also invites anyone with information regarding ARS Pharmaceuticals’s conduct to contact the firm. To learn more about the lawsuit, investors can visit the firm’s website at www.faruqilaw.com/SPRY or contact partner Josh Wilson directly.

The firm notes that participation in the lawsuit is not limited to those seeking appointment as lead plaintiff, and any eligible investor who purchased shares during the relevant period may potentially share in any recovery. Investors are encouraged to review their trading records to confirm their involvement and to preserve relevant documentation, including trade confirmations and account statements.

For those interested in learning more, Faruqi & Faruqi, LLP, can be reached at the numbers provided or through their website. The firm emphasizes that they have a long history of representing investors in securities litigation and recovering significant sums for shareholders.